It is estimated that slightly more than 300,000 Americans have been diagnosed with myeloproliferative neoplasms (MPNs). The three classic forms of BCR-ABL negative MPNs include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (MF), with PV being the most prevalent. Although MPNs can strike anyone at any age, most patients are afflicted in the sixth decade of life or later.
Although outside of allogeneic stem cell transplant, there is no cure for MPNs, there are medical therapies that can inhibit promiscuous signaling pathways caused by genetic mutations, reduce risk of complications, and improve symptom burden. In addition, clinical studies are underway to explore additional therapies.
Here, the Journal of the Advanced Practitioner in Oncology (JADPRO) presents Myeloproliferative Neoplasms (MPN) Updates, a monthly educational newsletter and enduring resource for advanced practitioners. As the editor of the program, I will share articles and news items containing the latest in treatment and management strategies. In the near future, we’ll take a look at the most relevant and potentially practice-changing results to come out of the 2016 ASH® Meeting on Hematologic Malignancies. In addition, in our next edition we’ll be presenting a video roundtable discussion with several of my distinguished colleagues on current issues in MPN.
Please feel free to share this newsletter with your colleagues, and don’t hesitate to get in touch with me with comments or suggestions through the JADPRO editors at email@example.com at any time.
Until next time, take a look at the links I’ve gathered for you here. I hope you find this to be a useful resource in your practice!
Lindsey Lyle, MS, PA-C
University of Colorado, Anschutz Medical Campus